It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
OTULIN is a deubiquitinase that specifically cleaves linear ubiquitin chains. Here we demonstrate that the ablation of Otulin selectively in keratinocytes causes inflammatory skin lesions that develop into verrucous carcinomas. Genetic deletion of Tnfr1, knockin expression of kinase-inactive Ripk1 or keratinocyte-specific deletion of Fadd and Mlkl completely rescues mice with OTULIN deficiency from dermatitis and tumorigenesis, thereby identifying keratinocyte cell death as the driving force for inflammation. Single-cell RNA-sequencing comparing non-lesional and lesional skin reveals changes in epidermal stem cell identity in OTULIN-deficient keratinocytes prior to substantial immune cell infiltration. Keratinocytes lacking OTULIN display a type-1 interferon and IL-1β response signature, and genetic or pharmacologic inhibition of these cytokines partially inhibits skin inflammation. Finally, expression of a hypomorphic mutant Otulin allele, previously shown to cause OTULIN-related autoinflammatory syndrome in humans, induces a similar inflammatory phenotype, thus supporting the importance of OTULIN for restraining skin inflammation and maintaining immune homeostasis.
OTULIN is a deubiquitinase for linear ubiquitin chains. Here the authors show, using genetic mouse models and single-cell RNA-sequencing, that deficiency of OTULIN in keratinocytes causes skin inflammation and verrucous carcinoma via the induction of keratinocyte death, thereby implicating a function of OTULIN in keratinocyte homeostasis.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details






1 VIB Center for Inflammation Research, Ghent, Belgium (GRID:grid.11486.3a) (ISNI:0000000104788040); Ghent University, Department of Biomedical Molecular Biology, Ghent, Belgium (GRID:grid.5342.0) (ISNI:0000 0001 2069 7798); Cancer Research Institute Ghent (CRIG), Ghent, Belgium (GRID:grid.510942.b)
2 VIB Center for Inflammation Research, Ghent, Belgium (GRID:grid.11486.3a) (ISNI:0000000104788040); Ghent University, Department of Biomedical Molecular Biology, Ghent, Belgium (GRID:grid.5342.0) (ISNI:0000 0001 2069 7798)
3 Karolinska Institutet, Department of Cell and Molecular Biology, Stockholm, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626)
4 VIB Center for Inflammation Research, Ghent, Belgium (GRID:grid.11486.3a) (ISNI:0000000104788040); Computer Sciences and Statistics, Ghent University, Department of Applied Mathematics, Ghent, Belgium (GRID:grid.5342.0) (ISNI:0000 0001 2069 7798)
5 VIB Center for Inflammation Research, Ghent, Belgium (GRID:grid.11486.3a) (ISNI:0000000104788040); Ghent University, Department of Biomedical Molecular Biology, Ghent, Belgium (GRID:grid.5342.0) (ISNI:0000 0001 2069 7798); University of Virginia, Center for Cell Clearance and Department of Microbiology, Immunology and Cancer Biology, Charlottesville, USA (GRID:grid.27755.32) (ISNI:0000 0000 9136 933X)